Molecular diagnostics firm Curetis this week announced the availability of new data on the clinical performance of its Unyvero P50 pneumonia cartridge in multi-pathogen infections.

Researchers from private laboratory medicine firm MVZ Dr. Eberhard & Partner in Dortmund, Germany, analyzed pneumonia patient samples using both Curetis' Unyvero P50 pneumonia cartridge and classical microbiology culture, and determined that Unyvero P50 had greater than 80 percent sensitivity with greater than 95 percent specificity for pathogen identification.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.